137 research outputs found
Corrigendum to ‘Ethical safety of deep brain stimulation: A study on moral decision-making in Parkinson's disease’ [Park. Relat. Disord. 21 (2015) 709e716]
No full textThe authors regret that the affiliation for Claudio Pacchetti was incorrect in the above published paper. The correct affiliation details are given above.
The authors would like to apologise for any inconvenience caused
A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot
No full textAnalisi dell'algoritmo SCHC per la compressione di pacchetti IP su reti Lo-Ra
No full textQuesto lavoro si pone l’obiettivo di fornire un’analisi approfondita dell’algoritmo Static Context Header Compression (SCHC), che rappresenta lo stato dell’arte per quanto riguarda la compressione e la frammentazione di pacchetti IP su reti Low-Power Wide-Area Network (LPWAN). Viene poi presentata l’implementazione che è stata realizzata e che si posiziona come una delle prime disponibili ad oggiope
Analisi dell'algoritmo SCHC per la compressione di pacchetti IP su reti Lo-Ra
No full textQuesto lavoro si pone l’obiettivo di fornire un’analisi approfondita dell’algoritmo Static Context Header Compression (SCHC), che rappresenta lo stato dell’arte per quanto riguarda la compressione e la frammentazione di pacchetti IP su reti Low-Power Wide-Area Network (LPWAN). Viene poi presentata l’implementazione che è stata realizzata e che si posiziona come una delle prime disponibili ad ogg
Acute and Chronic Effect of Acoustic and Visual Cues on Gait Training in Parkinson’s Disease: A Randomized, Controlled Study
No full textIn this randomized controlled study we analyse and compare the acute and chronic effects of visual and acoustic cues on gait performance in Parkinson’s Disease (PD). We enrolled 46 patients with idiopathic PD who were assigned to 3 different modalities of gait training: (1) use of acoustic cues, (2) use of visual cues, or (3) overground training without cues. All patients were tested with kinematic analysis of gait at baseline (T0), at the end of the 4-week rehabilitation programme (T1), and 3 months later (T2). Regarding the acute effect, acoustic cues increased stride length and stride duration, while visual cues reduced the number of strides and normalized the stride/stance distribution but also reduced gait speed. As regards the chronic effect of cues, we recorded an improvement in some gait parameters in all 3 groups of patients: all 3 types of training improved gait speed; visual cues also normalized the stance/swing ratio, acoustic cues reduced the number of strides and increased stride length, and overground training improved stride length. The changes were not retained at T2 in any of the experimental groups. Our findings support and characterize the usefulness of cueing strategies in the rehabilitation of gait in PD
Botulinum toxin and neuromotor rehabilitation: An intergrated approach to idiopathic cervical dystonia
No full text
Long-term evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease.
No full textMental disorders (MDs) are disabling complications of Parkinson disease (PD). We set out to demonstrate the short- and long-term efficacy of quetiapine, an antipsychotic drug, in controlling hallucinations and delusions in parkinsonian patients without worsening their motor function. Since current guidelines recommend that dopaminergic drugs be decreased or even withdrawn altogether upon the appearance of MDs, we also sought to establish whether quetiapine enables a modification of this common course of action, and hence improve the management of pre-existing motor complications in affected subjects. METHOD: Thirty-five PD patients with disabling MDs were enrolled in this open-label study. Motor function, MDs and cognitive state were evaluated before starting quetiapine therapy and after 1, 3, and 12 months of treatment. RESULTS: MDs significantly improved after 1, 3, and 12 months of quetiapine treatment. At the end of the study the mean daily dose of quetiapine (185 mg) did not produce significant changes in motor or cognitive function. Isolated hallucinations responded to low doses of quetiapine (110 mg daily), while delusions needed 265 mg daily. After 12 months, global dopaminergic therapy was reduced in 3 patients, modified (purely in terms of its components) in 17 patients, and increased in 15 patients. CONCLUSIONS: Quetiapine was effective in the treatment of hallucinations and delusions in PD. It did not worsen motor functions and allowed the dopaminergic treatment in PD patients affected by MDs to be managed safely
- …
